A Novo Nordisk-led study comparing CagriSema, its GLP-1 drug candidate for obesity, found that Eli Lilly’s Zepbound resulted in greater weight loss.

诺和诺德领导的一项研究比较了其用于治疗肥胖的GLP-1候选药物CagriSema，发现礼来公司的Zepbound带来了更大的减重效果。

The open-label, head-to-head trial analyzed the average weight loss among adults who received weekly injections of either CagriSema or Zepbound. After 84 weeks, the CagriSema group achieved a 20.2% reduction in weight, compared to the 23.6% weight loss with Zepbound.

开放标签、头对头试验分析了每周接受CagriSema或Zepbound注射的成年人的平均减重情况。84周后，CagriSema组体重减轻了20.2%，而Zepbound组体重减轻了23.6%。

Novo Nordisk

诺和诺德

announced

宣布

the phase 3 trial results Feb. 23. The trial included 809 adults with obesity and at least one comorbidity, according to the Denmark-based drugmaker.

2月23日公布了第三阶段试验结果。据这家总部位于丹麦的制药公司称，试验包括809名患有肥胖症且至少有一种合并症的成年人。

This trial is part of a multi-part clinical study on CagriSema including about 4,600 adults with obesity or overweight.

这项试验是一项关于CagriSema的多部分临床研究的一部分，包括大约4600名肥胖或超重的成年人。

In December, Novo Nordisk submitted CagriSema to the FDA for approval, and the drugmaker said a decision is expected by late 2026.

去年 12 月，诺和诺德向 FDA 提交了 CagriSema 的审批申请，该制药商表示预计将在 2026 年底做出决定。

Recommended Whitepaper

推荐的白皮书

Eli Lilly has launched a multidose version of its blockbuster weight loss drug Zepbound that gives patients a month’s worth…

礼来公司推出了一款多剂量版本的畅销减肥药 Zepbound，可以为患者提供一个月的用量……

Eli Lilly has reported positive results from its phase 3b Together-PsO trial evaluating the combined use of Taltz (ixekizumab) and…

礼来公司报告了其3b期Together-PsO试验的积极结果，该试验评估了Taltz（ixekizumab）与…的联合使用。

In a comparative study evaluating SGLT2 inhibitors and GLP-1 medications, the former drug class was associated with lower risk of…

在一项评估SGLT2抑制剂和GLP-1药物的对比研究中，前者与较低的……风险相关。